McDonald's shares slip after downgrade spurred by weight-loss drug popularity

McDonald's shares fell after Redburn Atlantic downgraded the stock from buy to sell, citing concerns that GLP-1 weight-loss drugs like Ozempic and Wegovy could reduce customer visits by up to 28 million annually, resulting in a $482 million revenue loss (0.9% of sales); the analysts believe lower-income consumers, a key McDonald's demographic, are particularly likely to reduce spending on eating out while using these drugs, and that pricing fatigue is compounding the issue, though other analysts suggest the impact may be limited in the near term due to the cost of such drugs.

Analysis

McDonald's Corporation (MCD) shares declined by up to 1.7% after Redburn Atlantic issued a two-notch downgrade from 'buy' to 'sell', primarily citing the underappreciated threat from GLP-1 weight-loss drugs. Redburn's analysis projects these drugs could lead to 28 million fewer customer visits annually for McDonald's, resulting in a $482 million revenue loss, or 0.9% of sales, with a particular concern for lower-income consumers—a key McDonald's demographic—who may permanently reduce dining-out expenditures. The report suggests this impact could grow from a 1% drag today to 10% or more over time, especially for brands with broad mass-market exposure.

Compounding these concerns are existing inflationary pressures and notable consumer 'pricing fatigue' from aggressive menu inflation, which has widened the cost differential between eating out and at home. While Redburn views GLP-1 drugs as significant 'demand disruptors,' with McDonald's being particularly exposed, BTIG analyst Peter Saleh offers a counterpoint, suggesting the near-term impact might be limited due to the high cost of these drugs for McDonald's core customers, though acknowledging potential future effects in three to four years. Current GLP-1 adoption is at 6% of U.S. adults, indicating potential for growth, and the overall market sentiment towards McDonald's in light of these developments is moderately negative, reflected by a sentiment score of -0.55.

Key Decisions for Investors

• Investors should closely monitor the adoption trajectory of GLP-1 drugs and McDonald's reported customer traffic, particularly within its value-sensitive demographic, given the potential for an escalating revenue impact from an initial 0.9% projection.
• Evaluate the dual headwinds of GLP-1 drug adoption and consumer pricing fatigue against McDonald's current valuation and strategic responses before making significant portfolio adjustments.
• Consider the recent 'sell' downgrade as a notable data point, weighing the long-term risks highlighted by Redburn Atlantic against alternative analyst views that suggest a more delayed impact from GLP-1 drugs.